Entera Bio (ENTX) AI Stock Analysis

• Market Cap: $82.72M
• Dividend Yield: N/A
• Average Volume (3M): 201.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: 191.23%
• EPS Growth: 2.17%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 45,452,168
• 10 Day Avg. Volume: 526,920
• 30 Day Avg. Volume: 201,408
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 315.34
• Enterprise Value/Gross Profit: 7.81K
• Enterprise Value/Ebitda: -9.39
• 1Y Price Target: $10.00
• Price Target Upside: 449.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: ―

Entera Bio's overall stock score reflects a balance between financial challenges and strategic advancements. The company's financial instability and cash flow issues weigh significantly on the score. However, positive corporate events and strong technical momentum provide some optimism, though valuation remains a concern due to negative earnings.

Positive Factors

Collaboration and Licensing

Entera Bio and OPKO Health have entered into a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic disorders.

Funding and Financial Support

OPKO purchased roughly 3.7 million ordinary shares of Entera for $8 million, providing funding for Entera's share of the development costs.

Market Opportunity

The collaboration with OPKO provides access to a promising anti-obesity candidate, funding, and favorable economics in a large and lucrative market.

Negative Factors

Clinical Development Risks

Risks include failure to advance EB613 or EB612 through clinical development in a timely manner and inability to secure a partner to optimize the commercial value of EB613.

Financial Performance

Entera reported a net loss per share mainly driven by higher than expected operating expenses.

Entera Bio Business Overview & Revenue Model

Company Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

How the Company Makes Money

Entera Bio generates revenue through the development and commercialization of its proprietary oral drug formulations. The company's key revenue streams include collaborations and licensing agreements with other pharmaceutical companies. These partners may provide upfront payments, milestone payments, and royalties based on the sales of successfully developed drugs. Entera Bio's business model relies heavily on research and development activities, strategic partnerships, and the potential commercialization of its pipeline products.

Entera Bio Financial Statement Overview

Summary

Entera Bio faces significant financial challenges, with persistent losses, negative cash flows, and dependency on external financing. The income statement shows erratic revenue growth and weak profit margins, while the balance sheet reflects moderate leverage but negative shareholder returns. Cash flow management issues further emphasize financial instability.

Income Statement

Entera Bio has struggled with profitability, evidenced by consistently negative net income and EBIT over the years. The gross profit margin is weak, and the net profit margin is negative due to significant operating losses. The revenue growth is erratic, with revenue fluctuating significantly, highlighting instability in revenue generation.

Balance Sheet

The company's financial stability is moderate with a low debt-to-equity ratio, indicating manageable leverage. However, the return on equity is negative due to net losses, which impacts shareholder value. The equity ratio suggests a reasonable proportion of assets financed by equity, but overall balance sheet performance is hampered by ongoing losses.

Cash Flow

Cash flow management presents challenges, with negative operating cash flow and free cash flow across periods, indicating cash burn issues. The free cash flow to net income ratio is also negative, reflecting inefficiencies in converting income into cash. Financing activities have been crucial for liquidity, highlighting dependency on external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	181.00K	0.00	134.00K	571.00K	365.00K
Gross Profit	9.00K	-56.00K	33.00K	198.00K	156.00K
EBITDA	-9.54M	-8.80M	-12.87M	-12.16M	-11.11M
Net Income	-9.54M	-8.89M	-13.07M	-12.19M	-9.98M
Balance Sheet
Total Assets	9.39M	11.77M	13.13M	25.99M	10.26M
Cash, Cash Equivalents and Short-Term Investments	8.66M	11.02M	12.31M	24.89M	8.59M
Total Debt	272.00K	390.00K	91.00K	302.00K	432.00K
Total Liabilities	1.31M	1.38M	1.37M	3.42M	3.60M
Stockholders Equity	8.08M	10.39M	11.75M	22.57M	6.67M
Cash Flow
Free Cash Flow	-6.82M	-7.33M	-12.55M	-9.08M	-10.48M
Operating Cash Flow	-6.82M	-7.31M	-12.50M	-9.06M	-10.42M
Investing Cash Flow	-3.00K	-17.00K	-102.00K	-17.00K	-86.00K
Financing Cash Flow	4.48M	6.04M	13.00K	25.38M	3.92M

Entera Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTX, the sentiment is Negative. The current price of 1.82 is below the 20-day moving average (MA) of 1.96, below the 50-day MA of 1.95, and below the 200-day MA of 2.00, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.53 is Neutral, neither overbought nor oversold. The STOCH value of 13.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENTX.

Entera Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.35B	-0.20	-44.53%	2.35%	30.18%	-1.17%
ENTX	50 Neutral	$82.72M	―	-82.22%	―	191.23%	2.17%
VTYX	41 Neutral	$200.38M	―	-48.56%	―	―	39.76%
JBIO	39 Underperform	$241.45M	―	-59.01%	32.04%	―	44.04%
TNYA	36 Underperform	$109.01M	―	-85.21%	―	―	38.94%
BDTX	33 Underperform	$136.64M	10.14	11.85%	―	―	―
ELTX	30 Underperform	$150.31M	―	-9999.00%	―	―	-4.60%

Entera Bio Corporate Events

Entera Bio Announces 2024 Financial Results and Updates

Entera Bio Ltd. announced its financial results and business updates for 2024, highlighting significant advancements in its oral peptide programs, including EB613 for osteoporosis, which is poised for a Phase 3 study pending FDA updates. The company also reported progress in its GLP-1/Glucagon and GLP-2 tablet programs, collaborating with OPKO Health to enhance its pipeline. Entera’s financial position was strengthened by investments, allowing it to fund operations into 2026, with a focus on regulatory and development activities.

Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon

On March 16, 2025, Entera Bio Ltd. entered into a collaboration and license agreement with OPKO Health, Inc. and OPKO Biologics Ltd. to develop an oral dual agonist GLP-1/glucagon peptide for treating obesity, metabolic, and fibrotic disorders. Under the agreement, Entera and OPKO will share development costs and proceeds, with Entera holding a 40% stake and OPKO 60%. Entera issued shares to OPKO to fund its share of development costs, and the collaboration aims to advance the first oral GLP-1/glucagon dual agonist into clinical trials, potentially impacting the treatment landscape for related disorders.